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Abstract
Placenta growth factor (PlGF) is a member of the vas-
cular endothelial growth factor family of cytokines that
control vascular and lymphatic endothelium develop-
ment. It has been implicated in promoting angiogenesis
in pathological conditions via signaling to vascular endo-
thelial growth factor receptor-1. PlGF expression is
induced by hypoxia and proinflammatory stimuli. Metal
responsive transcription factor 1 (MTF-1) was shown to
take part in the hypoxic induction of PlGF in Ras-trans-
formed mouse embryonic fibroblasts. Here we report that
PlGF expression is also controlled by NF-kB. We identi-
fied several putative binding sites for NF-kB in the PlGF
promoter/enhancer region by sequence analyses, and
show binding and transcriptional activity of NF-kB p65
at these sites. Expression of NF-kB p65 from a plasmid
vector in HEK293 cells caused a substantial increase of
PlGF transcript levels. Furthermore, we found that
hypoxic conditions induce nuclear translocation and
interaction of MTF-1 and NF-kB p65 proteins, suggesting
a role for this complex in hypoxia-induced transcription
of PlGF.
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MTF-1; nuclear factor kB; VEGF.
Introduction
The placenta growth factor (PlGF) is a member of a family
of structurally related angiogenic factors termed vascular
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endothelial growth factors (VEGF). VEGF, also referred to
as VEGF-A, is the founding member of this family and
was identified due to its ability to promote vascular per-
meability as well as vascular endothelial cell proliferation
and migration (Keck et al., 1989; Leung et al., 1989;
Lyden et al., 2001; Nagy et al., 2002). Other family mem-
bers include VEGF-B, VEGF-C, VEGF-D, VEGF-E and the
endocrine gland-derived VEGF (EG-VEGF) (Yancopoulos
et al., 2000; LeCouter et al., 2001). All factors are active
as dimeric glycosylated proteins. Homo- and hetero-
dimer formation involves cysteine residues that create a
so-called ‘cysteine knot’ (McDonald and Hendrickson,
1993). VEGF binds to the tyrosine kinase receptors
VEGFR-1 and VEGFR-2, and loss of VEGF-A or its recep-
tors results in abnormal angiogenesis and lethality during
development (Carmeliet et al., 1996; Ferrara et al., 1996;
Gerber et al., 1999a,b). In contrast, PlGF binds only to
VEGFR-1 (Park et al., 1994) and appears to be dispen-
sable for normal development but crucial for angio-
genesis during pathological conditions (Carmeliet et al.,
2001; Luttun et al., 2002a; Odorisio et al., 2002). In
humans, four isoforms of PlGF (PlGF-1 to 4) have been
identified. They are generated by alternative splicing and
differ in size and binding properties (Maglione et al.,
1993; Cao et al., 1997; Yang et al., 2003).
PlGF gene expression is inducible upon proinflamma-
tory stimuli as well as by the condition of low intracellular
oxygen tensions, termed hypoxia (Green et al., 2001;
Oura et al., 2003; Selvaraj et al., 2003). Several years
ago, it was found that the transcriptional regulation of
PlGF involves metal responsive transcription factor 1
(MTF-1, also termed metal response element binding
transcription factor 1, or in short, metal transcription fac-
tor 1) as the hypoxic upregulation of PlGF mRNA was
shown to be severely reduced in MTF-1-/- embryonic
fibroblasts (Green et al., 2001). MTF-1, a protein that is
conserved from insects to mammals, responds to diverse
stress signals by translocating from the cytoplasm to the
nucleus and binding to DNA sequence motifs termed
metal response elements (MREs) (Brugnera et al., 1994;
Lichtlen and Schaffner, 2001; Saydam et al., 2001; Zhang
et al., 2001). The study revealed several putative MREs
in the mouse and human PlGF upstream promoter region
(Green et al., 2001). Also, the oxygen-dependent subunit
of HIF-1, HIF-1a, was proposed to play a role in the
hypoxia-induced transcription of PlGF, based on experi-
ments with a constitutively active form of HIF-1a as well
as HIF-1a-deficient embryonic stem cells (Kelly et al.,
2003). Zhang et al. (2003) reported on PlGF as a target
gene of the forkhead/winged helix transcription factor
FoxD1 (BF-2) in the developing kidney stroma and iden-
tified a conserved HNF3b binding site, which bound to
bacterially-produced BF-2 protein in EMSA experiments.
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Figure 1 Transcription factor binding elements in the human
PlGF promoter/enhancer region.
(A) Schematic representation of the proximal promoter/enhancer
region of the human PlGF gene with transcription factor binding
sites indicated. kB (NF-kB binding site, present study), Sp1 (Sp1
binding site, predicted in Green et al., 2001), MRE (metal-
responsive element; Green et al., 2001, and present study), HRE
(hypoxia-responsive element, predicted in Green et al., 2001),
HNF3b (BF-2 binding site; Zhang et al., 2003). The four putative
kB sites and the five MREs, including three nucleotides of the
respective flanking regions on each side, were combined to cre-
ate the 4=kB(PlGF) and 5=MRE(PlGF) oligonucleotides, respec-
tively, which were used in the experiments shown in Figure 2
(see also materials and methods). (B) Sequences of the putative
kB-sites in the human PlGF promoter/enhancer region. Core rec-
ognition sequences are indicated in bold; deviations from a
commonly cited consensus (Leung et al., 2004) are indicated by
lower case letters.
Based on the proangiogenic role of PlGF in diverse
(patho-)physiological conditions, we reasoned that addi-
tional factors are likely to be involved in its transcription.
Angiogenesis occurs in physiological and pathological
conditions and is tightly regulated. Inflammatory cells
such as monocytes/macrophages or T lymphocytes are
involved in this process by secreting cytokines that exert
effects on endothelial cells (Naldini and Carraro, 2005).
NF-kB is a key player in the inflammatory response and
there are numerous reports on the role of NF-kB in angio-
genic processes (Scatena et al., 1998; Malyankar et al.,
2000; Klein et al., 2002; Ko et al., 2002; Patel et al.,
2005).
In the present study, we report on the influence of
NF-kB on the expression of PlGF in human embryonic
kidney (HEK) 293 cells. We show that the PlGF promoter/
enhancer region harbors DNA binding sites for NF-kB,
which are bound by NF-kB in a transcriptionally active
form. PlGF transcript levels rose substantially when
NF-kB p65 was overexpressed in HEK293 cells and
coexpression of NF-kB p65 and MTF-1 led to an even
further increase. We also report on a nuclear transloca-
tion and interaction of NF-kB p65 and MTF-1 during
hypoxic exposure and discuss a possible role of this
complex in hypoxia-induced transcription of PlGF.
Results
Characterization of the PlGF promoter/enhancer
region
A DNA segment of 1.7 kb length encompassing the
59-flanking region of the human PlGF gene (GenBank
accession number AC006530) was analyzed. Previously,
multiple MREs had been identified in the PlGF promoter
region (Green et al., 2001). A closer inspection of the
sequence also revealed the presence of several potential
kB-sites (Figure 1).
NF-kB associates with hPlGF promoter elements in
a transcriptionally active form
To investigate binding of NF-kB to the putative kB-ele-
ments, EMSA was performed using a probe combining
all potential kB-sites of the human PlGF gene (Figure 1).
Figure 2A shows specific binding of NF-kB to this probe
w4=kB (PlGF)x. To analyze whether NF-kB can drive tran-
scription from these sites, the combined kB-elements,
that were used for EMSA, were cloned into the OVEC
(oI ligonucleotide tor)-reporter plasmid (Westin et al.,vec
1987) and transcript levels were determined by nuclease
S1 protection assays. The background reporter signal
was somewhat increased when the empty reporter plas-
mid (OVEC-only) was co-transfected with pC-NF-kB p65
(Figure 2B, lane 2). This might reflect binding of NF-kB
to some fortuitous kB-site(s) in the backbone of the plas-
mid. The OVEC reporter gene system is generally accu-
rate and reliable and was therefore used here as well,
despite the elevated signal of the negative control, which
had to be subtracted. When 4=kB(PlGF)-OVEC was co-
transfected with pC-NF-kB p65, the signal intensity
markedly increased compared to OVEC-only (Figure 2B,
lane 3), which indicates binding and transcriptional activ-
ity of NF-kB from this ‘mini-promoter’.
To test the responsiveness of the endogenous PlGF
gene to NF-kB, quantitative RT-PCR was performed.
PlGF transcript levels increased about fivefold upon tran-
sient expression of NF-kB p65 in HEK293 cells that were
grown in 5% FBS (Figure 2C). MTF-1 was shown in ear-
lier studies to activate PlGF transcription during hypoxia
in Ras-transformed mouse embryonic fibroblasts (Green
et al., 2001). However, exposure to 1% oxygen for 16 h
did not show an effect on PlGF transcript levels in
untransfected HEK293 cells or HEK293 cells over-
expressing MTF-1 or NF-kB p65 alone or coexpressed
(data not shown). The human placental cell line 3A-subE,
human aortic endothelial cells (HAECs) and human
umbilical vein endothelial cells (HUVECs) were tested
under the same hypoxic conditions but neither of these
cell types showed an upregulation of PlGF transcripts by
quantitative RT-PCR (data not shown). This probably
reflects cell type specificity of the hypoxic induction of
PlGF transcription.
Transient expression of MTF-1 did not lead to an upre-
gulation of PlGF transcript levels in HEK293 cells (Figure
2C). Nevertheless, a further increase of PlGF transcript
levels was observed when NF-kB p65 was co-expressed
with MTF-1 (Figure 2C). To assess whether MTF-1 exerts
its effect via binding to its designated DNA recognition
sequences within the PlGF promoter/enhancer region, or
rather exerts its effect via NF-kB and without DNA bind-
ing, EMSA was performed with a probe combining all
NF-kB acts on the PlGF promoter and interacts with MTF-1 867
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Figure 2 NF-kB p65 binds to the PlGF promoter in a transcriptionally active form.
(A) Electrophoretic mobility shift assay (EMSA) showing DNA binding of NF-kB p65 to a probe that combines all potential kB-sites
of the human PlGF promoter/enhancer region w4=kB (PlGF)x and to a probe combining the kB-sites of HIV w2=kB(HIV), positive
controlx. Specific binding was determined by competition with the unlabeled 2=kB(HIV) oligonucleotide and an unspecific, unlabeled
competitor (binding site for yeast Gal4). (B) S1 nuclease protection assay with the 4=kB(PlGF)-OVEC reporter, the OVEC-only control
and CMV-OVEC as reference. Cells were kept in 5% FBS prior to RNA isolation. The reporter signal ratio increased above the OVEC-
only background upon overexpression of NF-kB p65. (C) Increased levels of endogenous PlGF transcript upon transient expression
of NF-kB p65 and MTF-1 in HEK293 cells. Cells were transfected with 4 mg of pC-NF-kB p65, pC-hMTF-1 or the empty vector (pC-
DNA3). pC-DNA3 had been used for the cloning of both pC-NF-kB p65 and pC-hMTF-1. The final amount of transfected DNA was
the same in all cases. Cells were kept in 5% FBS prior to RNA isolation. Transcript levels were determined by quantitative real-time
PCR. TATA-binding protein (TBP), eukaryotic elongation factor 1A1 (EEF1A1) and transferrin receptor (TFRC) served as reference
genes. The bars represent the mean of three independent experiments. (D) EMSA showing DNA binding of MTF-1 to a probe that
combines all potential metal response elements of the human PlGF promoter/enhancer region w5=MRE (PlGF)x and to a probe with
four tandem repeats of MREd, a strong MRE of the mouse metallothionein I promoter. Several bands were detected in both cases,
probably because some of the binding sites are preferentially bound by MTF-1. Specific binding was determined by competition with
an unlabeled MRE-s oligonucleotide, and with unspecific, unlabeled competitors 2=kB(HIV) and a binding site for yeast Gal4.
putative MREs w5=MRE(PlGF), Figure 1x. Figure 2D
shows that MTF-1 can bind to several of the MREs, sug-
gesting that MTF-1 associates with the PlGF promoter
by direct DNA binding.
Taken together, the results suggest a joint action of
MTF-1/NF-kB p65 on the PlGF promoter and prompted
us to test for protein interaction of the two factors.
MTF-1 and NF-kB p65 interact in the nuclei of
stimulated cells
To investigate a possible protein interaction between
MTF-1 and NF-kB, co-immunoprecipitations and South-
western analyses with nuclear and cytoplasmic HEK293
cell lysates were performed. In Southwestern analysis,
co-immunoprecipitated endogenous MTF-1 was detect-
ed by binding to a labeled MRE oligonucleotide. Neither
for overexpressed (Figure 3A) nor for endogenous pro-
teins (Figure 3B) was an interaction observed in serum-
starved, resting cells. Tumor necrosis factor-a (TNF-a)
and zinc are known to be specific inducers of nuclear
translocation and activation of NF-kB and MTF-1,
respectively. Simultaneous treatment of HEK293 cells
with these inducers led to a detectable association of
both overexpressed (Figure 3A) and endogenous (Figure
3B) MTF-1 and NF-kB p65 proteins in the nuclear frac-
tions. The control experiments presented in Figure 3C
ruled out nonspecific binding and nonspecific effects of
reaction components. Single treatments with TNF-a or
zinc did not promote the co-immunoprecipitation of
MTF-1 or NF-kB p65, respectively (Figure 3A and B).
Interestingly, the interaction between MTF-1 and NF-kB
also occurred after hypoxic exposure of the cells (Figure
3A and B). Therefore, hypoxia seems to be a common
stimulus for the nuclear translocation and interaction of
MTF-1 and NF-kB.
Hypoxia induces nuclear localization of MTF-1 and
NF-kB p65
To verify the effect of hypoxia on the cellular distribution
of NF-kB p65 and MTF-1, immunofluorescence experi-
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Figure 3 NF-kB interacts with MTF-1 in the nuclei of stimulated cells.
(A) HEK293 cells were transfected with 5 mg of pC-NF-kB p65 and VSV- (vesicular stomatitis virus) epitope-tagged pC-hMTF-1-VSV
and serum-starved 24 h prior to various treatments of cells, as indicated. Immunoprecipitations (IP) were done with an anti-VSV
antibody for MTF-1 and anti-NF-kB p65. a, antibody; IB, immunoblot with indicated antibody. (B) Endogenous protein interaction
was analyzed by Southwestern. HEK293 cells were serum-starved 24 h prior to preparations of nuclear and cytoplasmic lysates. NF-
kB p65 was immunoprecipitated following treatments as indicated. MTF-1 was detected by hybridization to a radioactively labeled
consensus MRE probe (designated MRE-s). (C) Controls with protein extracts of untransfected (left panel) and pC-MTF-1-VSV trans-
fected (right panel) HEK293 cells, demonstrating specificity of the results shown in (A) and (B). Slot 1 reveals that neither NF-kB p65
nor MTF-1-VSV bind nonspecifically to protein A Sepharose beads. Slot 2 represents controls with beads and antibody (left panel:
a-NF-kB p65; right panel: a-VSV), and without protein. Slot 3 shows that the protein extracts contained NF-kB p65 and MTF-1-VSV
protein, respectively. NF-kB was enriched by immunoprecipitation for better detection (beadsqantibodyqprotein).
ments were performed. HEK293 cells were transiently
transfected with expression vectors encoding NF-kB p65
and VSV-tagged MTF-1. Sixteen hours after transfection,
cells were serum-starved in DMEM-BSA (0.5%) for 24 h.
In untreated cells, both proteins localized predominantly
to the cytoplasm (Figure 4). Elevated zinc concentrations
caused nuclear translocation of MTF-1, but not of NF-kB
p65. Conversely, TNF-a treatment induced rapid NF-kB
p65 nuclear translocation, but had no effect on MTF-1,
which remained cytoplasmic (Figure 4). However, when
cells were exposed to hypoxia, nuclear translocation of
both MTF-1 and NF-kB p65 was observed (Figure 4).
These results show that in serum-deprived, normoxic
HEK293 cells, NF-kB p65 and MTF-1 reside in the cyto-
plasm, while hypoxic conditions lead to nuclear trans-
location of both proteins.
Discussion
The expression of placenta growth factor (PlGF) can
potentially be controlled at several levels. A rather poorly
understood step is the transcriptional regulation of the
PlGF gene. Here we report that NF-kB is likely to be
involved in this transcriptional regulation. NF-kB bound
to kB-sites of the PlGF gene in vitro and could drive tran-
scription of PlGF when transiently expressed in HEK293
cells. We found that coexpressing NF-kB p65 and MTF-
NF-kB acts on the PlGF promoter and interacts with MTF-1 869
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Figure 4 Hypoxia induces nuclear translocation of MTF-1 and
NF-kB p65.
Immunofluorescence experiments showing subcellular distribu-
tion of NF-kB p65 and MTF-1. pC-hMTF-VSV and, to obtain
similar fluorescence signal intensities, also pC-NF-kB p65 were
transfected into HEK293 cells. Cells were serum-starved for 24 h
and either left untreated, exposed to hypoxia (4 h), or treated
with 200 mM ZnCl2 (2 h) or 20 ng/ml TNF-a (30 min). MTF-1 is
shown in green (left panel), NF-kB p65 is shown in red (second
left panel). DNA was stained with 49,69-diamino-2-phenylindole
(DAPI, right panel, blue).
1, a protein with an established role in PlGF transcription,
resulted in a further increase of PlGF transcript levels.
The two proteins show a nuclear interaction and hypoxia
is a common stimulus for nuclear translocation and inter-
action of NF-kB and MTF-1.
Evidence has accumulated for a role of NF-kB in
angiogenic processes during hypoxia and inflammation
(Klein et al., 2002; Ko et al., 2002; Kofler et al., 2005;
Patel et al., 2005). Our findings suggest that NF-kB sig-
naling can promote its proangiogenic effects by upre-
gulating PlGF transcription. It was previously demon-
strated that NF-kB regulates proangiogenic molecules
such as IL-8 and the best-studied VEGF family member,
VEGF-A (Mukaida et al., 1994; Huang et al., 2000; Ko
et al., 2002). Dominant negative forms of NF-kB/RelA
decreased VEGF mRNA levels in human ovarian
and breast cancer cells (Huang et al., 2000; Shibata et
al., 2002). Advanced glycation end products (AGE),
which form at an accelerated rate in diabetes, induce
angiogenesis by signaling to VEGF via NF-kB (Okamoto
et al., 2002). It was reported that PlGF potentiates bio-
activity of VEGF (Park et al., 1994), possibly by the for-
mation of heterodimers. A common regulatory signaling
pathway could provide a mechanism to coordinate the
interplay of the two factors.
Our studies hint at an involvement of an NF-kB/MTF-1
complex in the transcription of PlGF under hypoxic con-
ditions, while a role of MTF-1 in the transcription of PlGF
was reported before. The previous MTF-1 study was
undertaken in Ras-transformed MEFs and demonstrated
the necessity of MTF-1 for the hypoxic upregulation of
PlGF in this cell type. Recently, it was shown that MTF-
1 null xenograft tumors had decreased tumor vessel den-
sities as compared to wild-type xenografts, which might
reflect the positive contribution of MTF-1 to PlGF expres-
sion (Haroon et al., 2004). We detected a basal level of
PlGF transcripts in HEK293 cells, which was stimulated
by both overexpression of NF-kB p65 and coexpression
of NF-kB p65 and MTF-1 (Figure 2C). Yet, in either case
we could not observe a hypoxic induction of PlGF tran-
scription (data not shown), demonstrating cell type spec-
ificity of this process. Nevertheless, we observed nuclear
translocation and interaction of NF-kB and MTF-1 upon
hypoxia in HEK293 cells. Regarding the additive effect of
NF-kB and MTF-1 coexpression on PlGF transcript lev-
els, the results suggest a joint action of the two factors
on the PlGF promoter, which might play a role in the
hypoxic induction of PlGF in certain cell types. However,
if both factors would be involved in the hypoxic upre-
gulation of PlGF, the formation of an NF-kB/MTF-1 pro-
tein complex would not constitute by itself the specificity
of the hypoxic signal. This is also underlined by the
observation that this interaction was not only taking
place in HEK293 cells subjected to hypoxia, but also in
cells that had been treated simultaneously with TNF-a
and zinc (Figure 3). Interestingly, Kelly et al. (2003) have
implicated a role of HIF-1a for the hypoxic upregulation
of PlGF. In light of the data presented here, it appears
likely that different factors help to activate the PlGF pro-
moter/enhancer region under hypoxia, possibly in a cell-
type-specific manner. In line with such a cell-type
specificity, hypoxic upregulation of VEGF transcription,
commonly referred to as a HIF-dependent process, was
shown to be HIF-1-independent in colon cancer cells
(Mizukami et al., 2004). Moreover, hypoxia-induced but
HIF-independent upregulation of erythroid 5-aminolevu-
linate synthase (Hofer et al., 2003) suggests the exis-
tence of different mechanisms for this process in given
cell types.
Expression of PlGF and other VEGFs is certainly a
complex process with several levels of regulation and it
has to be assessed for each of the diverse (patho-)phys-
iological conditions where VEGFs play a role. The results
presented here constitute a basic finding and could,
along with further studies, give new insights into the reg-
ulation of PlGF expression during inflammation and
hypoxia. PlGF expression has been proposed as a thera-
peutic target, on one hand to induce revascularization of
ischemic tissues, and on the other hand to block uncon-
trolled angiogenesis and inflammation in cancer and
other diseases (Luttun et al., 2002b,c).
Materials and methods
Cell cultures and treatments
HEK293 cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) with 5% fetal bovine serum (FBS), 1% L-glu-
tamine and 1% penicillin/streptomycin (Invitrogen, Carlsbad,
USA). For serum-starvation, FBS was replaced by 0.5% bovine
serum albumin (BSA). Transfections were done by the calcium-
phosphate method on 100-mm-diameter dishes at 60% cell
confluency. Where indicated, cells were subjected to hypoxia
870 M. Cramer et al.
Article in press - uncorrected proof
(1% O2), treated with 200 mM ZnCl2 and/or human TNF-a (20
ng/ml; R&D Systems, Minneapolis, USA) for up to 16 h.
Electrophoretic gel mobility shift assay (EMSA)
EMSAs were performed as described previously (Gunes et al.,
1998). Nuclear protein extracts of HEK293 cells, transfectedwith
10 mg of pC-NF-kB p65 or pC-hMTF-1, were used for binding
reactions. To generate 4=kB(PlGF), the following oligomers were
first cloned into SacI/XhoI digested pGL3-basic (Promega,
Madison, USA) and subsequently cut out by appropriate restric-
tion enzymes: 59-CGA GCC ACA GGG GGC TGC CCC GCA
GGC AGG GGT GCT CTC GGA GGC–39, 59-ACC CCT GCC
TGC GGG GCA GCC CCC TGT GGC TCG AGC T–39,
59-TAG GAA TCC CTT GGC GCC AGG GGC TCC CCG GGG
GAG–39 and 59-TCG ACT CCC CCG GGG AGC CCC TGG CGC
CAA GGG ATT CCT AGC CTC CGA GAG C–39. To generate
5=MRE(PlGF) the same strategy was employed using the fol-
lowing oligomers: 59-CGA GGT TCC TGC AGC CTG GGG CAG
GCG TGC AGA CTC ACA TGC CCA TGC ACA CG–39, 59-ATG
TGA GTC TGC ACG CCT GCC CCA GGC TGC AGG AAC CTC
GAG CT–39, 59-CGC AGA TGC ACA CAG ACC CAC AGA TGC
GCG CAC ACA CAC G–39 and 59-TCG ACG TGT GTG TGC
GCG CAT CTG TGG GTC TGT GTG CAT CTG CGC GTG TGC
ATG GGC–39. Sequences of control probes (sense strands):
2=kB(HIV): 59-AAT TCG GGA CTT TCC CAT CGG GAC TTT
CC–39; MRE-s: 59-CGA GGG AGC TCT GCA CAC GGC CCG
AAA AGT G–39; yeast Gal4 binding site: 59-TCC GGA GGA CTG
TCC TCC GG–39.
S1 nuclease protection assay
The S1 nuclease protection assay was performed as described
previously (Weaver and Weissmann, 1979; Westin et al., 1987).
To generate the reporter gene 4=-kB(PlGF)-OVEC, the same
oligomers as described for EMSA were cloned into SacI/Sal
I-digested pOVEC (Westin et al., 1987). HEK293 cells were
transfected with 10 mg reporter plasmid, 0.5 mg reference plas-
mid (CMV-OVEC-REF) and 4 mg of pC-NF-kB p65 or pC-DNA3.
The gels were visualized using a PhosphorImager (Molecular
Dynamics, Sunnyvale, USA).
Quantitative real-time PCR
HEK293 cells were transfected with 4 mg of pC-NF-kB p65, pC-
hMTF-1 or pC-DNA3. Precipitates were washed off after 14 h
and cells harvested after an additional 24 h incubation in 5%
FBS. After isolation (RNeasy Mini Kit, Qiagen, Hilden, Germany),
10 mg RNA were treated with DNase (DNA-free, Ambion, Aus-
tin, USA) according to the manufacturer’s protocol. Purity and
integrity of RNA was assessed on the Bioanalyzer (Agilent, Palo
Alto, USA). Four-hundred ng RNA were used for cDNA synthesis
by Superscript II RNase H Reverse Transcriptase (Invitrogen)
following the supplier’s instructions. Quantitative real-time PCRs
were performed on the ABI PRISM 7900HT Sequence Detection
System using SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, USA) with primers as determined by Primer
Express software. PlGF primers were designed to potentially
amplify transcripts of all known isoforms. PlGF: 59–TGT TCA
GCC CAT CCT GTG TC–39 and 59–ACA GTG CAG ATT CTC ATC
GCC–39. Reference genes: TFRC (transferrin receptor): 59–CAT
TTG TGA GGG ATC TGA ACC A–39 and 59–CGA GCA GAA TAC
AGC CAC TGT AA–39; TBP (TATA-binding protein): 59–GCCCGA
AAC GCC GAA TAT A–39 and 59–CGT GGC TCT CTT ATC CTC
ATG A–39; EEF1A1 (eukaryotic elongation factor 1A1): 59–AGC
AAA AAT GAC CCA CCA ATG–39 and 59–GGC CTG GAT GGT
TCA GGA TA–39. PCR efficiency was determined by the means
of standard curves and data analyzed with SDS Software v2.2
by the DDCt method and taking the geometric mean of the DDCt
values from the three reference genes. In given conditions, TFRC
expression has been reported to respond to inflammatory pro-
cesses (Tomkins, 2003) and might therefore be influenced by
overexpression of NF-kB p65. However, the change of TFRC
transcript levels in pC-DNA3 (empty control vector) transfected
versus NF-kB p65 overexpressing HEK293 cells was as low as
1.12"0.07-fold (average with standard deviation, measurements
in triplicate, ns3), most likely reflecting small experimental fluc-
tuations and not a physiological effect. Analysis and calculations
for TFRC were done as described above. EEF1A1 and TBP
served as reference genes.
Co-immunoprecipitation (Co-IP) and immunoblotting
The antibody against NF-kB p65 (sc-372) was purchased from
Santa Cruz Biotechnology (Santa Cruz, USA). The anti-VSV anti-
body for VSV- (vesicular stomatitis virus) epitope-tagged MTF-1
was purchased from Sigma (St. Louis, USA; V5507). Cell lysates
were prepared in 20 mM HEPES pH 7.9, 25% glycerol, 0.25 M
NaCl, 1 mM EDTA for nuclear fractions, and in 10 mM HEPES
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA for cytoplasmic
fractions, supplemented with 2.5 mM DTT, 5 mg/ml leupeptin
and 1.2 mM PMSF. Four-hundred mg total protein were used for
Co-IP and incubated with 2.5 ml of antibody for 1 h, followed
by 30 min incubation with 50% (v/v) Protein A sepharose. Pre-
cipitates were washed six times with EBC-170 and fractionated
on 10% SDS–polyacrylamide gels (Bio-Rad, Hercules, USA).
Southwestern blot analysis
Southwestern blot analysis was done as previously described
(Radtke et al., 1993), except that proteins were immunopreci-
pitated with a-NF-kB p65 antibody prior to fractionation on
SDS–polyacrylamide gels.
Indirect immunofluorescence
Indirect immunofluorescence and fluorescencemicroscopywere
performed as described previously (Saydam et al., 2001). The
antibody for NF-kB p65 was purchased from Santa Cruz Bio-
technology (sc-372).
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